Advertisement

Topics

Top Pharmaceutical Companies in Japan Reports

10:22 EDT 26th September 2018 | BioPortfolio

Intercept Pharmaceuticals Inc ICPT Financial and Strategic SWOT Analysis Review [Report Updated: 27032018] Prices from USD $125

Intercept Pharmaceuticals Inc ICPT Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that...

Daiichi Sankyo Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 13042018] Prices from USD $250

SummaryDaiichi Sankyo Inc Daiichi Sankyo, a subsidiary of Daiichi Sankyo Company Ltd is a healthcare products provider that discovers and develops medicines for cardiovascular and metabolic disorders. The company's products comprise amlodipine, laninamivir, prasugrel, olmesartan esomeprazole, carvedilol and vemurafenib. It develops medicines for various therapeutic classes, such as atherosclerosis...

Eisai Inc Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 30032018] Prices from USD $350

Eisai Inc Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Eisai Inc Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Eisai Inc since Januar...

Intercept Pharmaceuticals Inc ICPT Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 25042018] Prices from USD $250

SummaryIntercept Pharmaceuticals Inc Intercept is a biopharmaceutical company that researches, develops and commercializes treatments for nonviral, progressive liver diseases. It develops products using its proprietary bile acid chemistry. The company's lead product candidate, obeticholic acid OCA, is a bile acid analog and firstinclass agonist of the farnesoid X receptor. The company owns worldwi...

Takeda Pharmaceutical Company Limited Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 23042018] Prices from USD $350

Takeda Pharmaceutical Company Limited Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Takeda Pharmaceutical Company Limited Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partn...

Otsuka Pharmaceutical Co., Ltd. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 26062018] Prices from USD $350

Otsuka Pharmaceutical Co., Ltd. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Otsuka Pharmaceutical Co., Ltd. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership trans...

Intercept Pharmaceuticals Inc ICPT Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 06072018] Prices from USD $250

SummaryIntercept Pharmaceuticals Inc Intercept is a biopharmaceutical company that researches, develops and commercializes treatments for nonviral, progressive liver diseases. It develops products using its proprietary bile acid chemistry. The company's lead product candidate, obeticholic acid OCA, is a bile acid analog and firstinclass agonist of the farnesoid X receptor. The company owns worldwi...

Eisai Inc Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 23042018] Prices from USD $350

Eisai Inc Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Eisai Inc Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Eisai Inc since Januar...

Eisai Co., Ltd. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 23042018] Prices from USD $350

Eisai Co., Ltd. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Eisai Co., Ltd. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Eisai Co.,...

20182023 Malaysia Cytotoxic Drug Market Report Status and Outlook [Report Updated: 05032018] Prices from USD $3360

In 2017, the Cytotoxic Drug market size was xx million USD in Malaysia, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023.In Malaysia market, the top players include Roche Eli Lilly Celgene Sanofi eisai Sumitomo Dainippon Pharma Merck Seattle Genetics Takeda Haosoh Pharma Novartis AstraZeneca Jazz Pharma Spectrum PharmaSplit b...

Astellas Pharma Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 23042018] Prices from USD $350

Astellas Pharma Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Astellas Pharma Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by ...

Sumitomo Dainippon Pharma Co Ltd 4506 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 25042018] Prices from USD $250

SummarySumitomo Dainippon Pharma Co Ltd Sumitomo Dainippon, a subsidiary of Sumitomo Chemical Co., Ltd, develops manufacturers, purchases, sells, imports and exports pharmaceutical products. The company focuses on major therapeutic areas which include central nervous system CNS, cardiovascular, diabetes, oncology, respiratory psychiatry and neurology and infectious diseases. It also offers veterin...

20182023 India Cytotoxic Drug Market Report Status and Outlook [Report Updated: 05032018] Prices from USD $3360

In 2017, the Cytotoxic Drug market size was xx million USD in India, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023.In India market, the top players include Roche Eli Lilly Celgene Sanofi eisai Sumitomo Dainippon Pharma Merck Seattle Genetics Takeda Haosoh Pharma Novartis AstraZeneca Jazz Pharma Spectrum PharmaSplit by prod...

20182023 Philippines Cytotoxic Drug Market Report Status and Outlook [Report Updated: 05032018] Prices from USD $3360

In 2017, the Cytotoxic Drug market size was xx million USD in Philippines, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023.In Philippines market, the top players include Roche Eli Lilly Celgene Sanofi eisai Sumitomo Dainippon Pharma Merck Seattle Genetics Takeda Haosoh Pharma Novartis AstraZeneca Jazz Pharma Spectrum PharmaS...

20182023 United States Cytotoxic Drug Market Report Status and Outlook [Report Updated: 05032018] Prices from USD $3360

In 2017, the Cytotoxic Drug market size was xx million USD in United States, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023.In United States market, the top players include Roche Eli Lilly Celgene Sanofi eisai Sumitomo Dainippon Pharma Merck Seattle Genetics Takeda Haosoh Pharma Novartis AstraZeneca Jazz Pharma Spectrum Pha...

20182023 China Cytotoxic Drug Market Report Status and Outlook [Report Updated: 05032018] Prices from USD $3360

In 2017, the Cytotoxic Drug market size was xx million USD in China, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023.In China market, the top players include Roche Eli Lilly Celgene Sanofi eisai Sumitomo Dainippon Pharma Merck Seattle Genetics Takeda Haosoh Pharma Novartis AstraZeneca Jazz Pharma Spectrum PharmaSplit by prod...

Eisai Co., Ltd. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 17022018] Prices from USD $350

Eisai Co., Ltd. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Eisai Co., Ltd. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Eisai Co.,...

Acute Myeloid Leukaemia:KOL Insight [Report Updated: 01022018] Prices from USD $8495

How will four newly approved therapies transform treatment of AML?For decades, there were no approved treatments for acute myeloid leukaemia AML other than chemotherapies. The past year has witnessed the approval of four new therapies for AML; Novartis' Rydapt, Celgene/Agios' Idhifa, Jazz Pharma's Vyxeos and Pfizer's Mylotarg. How are these agents faring on the market so far and will more personal...

Takeda Pharmaceutical Company Limited Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 17022018] Prices from USD $350

Takeda Pharmaceutical Company Limited Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Takeda Pharmaceutical Company Limited Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partn...

Astellas Pharma Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 18022018] Prices from USD $350

Astellas Pharma Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Astellas Pharma Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by ...

Intercept Pharmaceuticals Inc ICPT Financial and Strategic SWOT Analysis Review [Report Updated: 21022018] Prices from USD $125

Intercept Pharmaceuticals Inc ICPT Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that...

Intercept Pharmaceuticals Inc ICPT Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 15022018] Prices from USD $250

SummaryIntercept Pharmaceuticals Inc Intercept is a biopharmaceutical company that researches, develops and commercializes treatments for nonviral, progressive liver diseases. It develops products using its proprietary bile acid chemistry. The company's lead product candidate, obeticholic acid OCA, is a bile acid analog and firstinclass agonist of the farnesoid X receptor. The company owns worldwi...

Advertisement
Quick Search
Advertisement
Advertisement

 

review and buy Top Pharmaceutical Companies in Japan market research data and corporate reports here